Avanos Medical, Inc.

NYSE:AVNS

Medical - Devices

Healthcare
$24.99 +0.22%

+$0.06 today

Market cap
$1.17B
Beta
1.57
P/E (TTM)
-16.7
EPS (TTM)
-$1.50
52W Low $9.30High $25.49

Volume 0.43M

Average 1.49M

AVNS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Avanos Medical, Inc.NYSE: AVNS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 48.5%

Gross margin was 48.5% in Q1 FY2026, down 5.1 pp from a year earlier. On a trailing-twelve-month basis it was 48.6%, down 6.2 pp year over year. Over 3 fiscal years it narrowed by 7.9 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
48.5%+1.0 pp QoQ
Last fiscal yearDec 2025
49.8%-5.7 pp YoY
LTMMar 2026
48.6%-6.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-5.1 pp——
1 year-5.7 pp——
3 years-7.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
49.8%
Year-over-year change
-5.7pp

Gross Margin vs competitors

How AVNS compares with its peers on the latest reported figures

  • AVNS's LTM Mar 2026 gross margin of 48.6% is the 6th highest of the 11 companies compared; the peer median is 50.0%.
  • Its year-over-year change of -6.2 pp is the lowest of 11, against a peer median of +0.6 pp.
  • Over three fiscal years its change of -7.9 pp compares with a peer median of +0.7 pp.
AVNS Competitors Peer median
Gross Margin for AVNS and competitors
Company Period LTM level YoY 3-year change
CBLLCeriBell, Inc.LTM Mar 202687.7% +0.5 pp+5.0 pp
BVSBioventus Inc.LTM Mar 202667.8% +0.6 pp+2.7 pp
CLPTClearPoint Neuro, Inc.LTM Mar 202661.8% +0.6 pp-4.5 pp
CYHCommunity Health Systems, Inc.LTM Mar 202653.7% +11.9 pp-31.5 pp
CTKBCytek Biosciences, Inc.LTM Mar 202651.7% -3.2 pp-9.7 pp
AVNSAvanos Medical, Inc.LTM Mar 202648.6% -6.2 pp-7.9 pp
LABStandard BioTools Inc.LTM Mar 202648.3% -1.2 pp+12.0 pp
PACBPacific Biosciences of California, Inc.LTM Mar 202637.1% +20.9 pp-6.5 pp
VREXVarex Imaging CorporationLTM Apr 202633.6% -0.2 pp+1.4 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-11.9% +506.2 pp+0.0 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
Peer median (excluding AVNS) 50.0%+0.6 pp+0.7 pp

Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue744.6M684.1M673.3M687.8M701.2M
Cost of Revenue364.7M289.9M293.6M306.5M352.2M
Gross Profit379.9M394.2M379.7M381.3M349M
Gross Margin51.0%57.6%56.4%55.4%49.8%
Research & Development32.3M30.6M27.2M26.2M23.1M
Selling, General & Admin260.8M323.1M287.5M315.1M218.3M
Operating Expenses293.1M352.3M314.7M341.3M410.6M
Depreciation & Amortization38.3M41.1M43.5M45.5M29M
EBITDA48.9M77.8M50.6M(345.6M)(33.2M)
EBITDA Margin6.6%11.4%7.5%-50.2%-4.7%
Operating Income86.8M41.9M65M40M(61.6M)
Operating Margin11.7%6.1%9.7%5.8%-8.8%
Interest Income200K1.2M2.9M5.1M3.2M
Interest Expense3.3M10M15M12.2M4M
Other Income / Expenses(79.5M)(15.2M)(72.9M)(443.3M)(4.6M)
Income Before Tax7.3M26.7M(7.9M)(403.3M)(66.2M)
Pre-Tax Margin1.0%3.9%-1.2%-58.6%-9.4%
Income Tax Expense1M5.2M2M(17M)1.7M
Net Income6.3M50.5M(61.8M)(392.1M)(67.9M)
Net Margin0.8%7.4%-9.2%-57.0%-9.7%
EPS (Basic)0.131.08(1.33)(8.53)(1.46)
EPS (Diluted)0.131.07(1.33)(8.53)(1.46)
Weighted Avg Shares48.1M46.9M46.6M46M46.4M
Weighted Avg Shares (Diluted)48.6M47.3M46.6M46M46.4M

Avanos Medical, Inc.

NYSE:AVNS

Intrinsic Alpha fair value

Locked

Current Price

$24.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.